follicular lymphoma | Relapsed/Refractory follicular lymphoma

Relapsed/Refractory follicular lymphoma

Follicular lymphoma is a type of non-Hodgkin's lymphoma that involves the abnormal growth of B lymphocytes (b lymphocytes). Lymphocytes with abnormal cell growth can move around the fuselage and form tumors, known as lymphoma, in the lymph nodes, spleen, bone marrow, blood or other organs. It is usually slow to grow but not curable in most cases.

Relapsed or refractory follicular lymphoma occurs when the cancer is not cured with the primary settlement request or returns after a period of remission. Patients may notice signs of cancer growth, such as fatigue, loss of appetite, or enlarged lymph nodes.

Relapsed follicular Cancer
A relapse is a term used to describe the dismissal of a disease after claiming a settlement. In follicular cancer This means that the abnormal cell that the increase improves at the beginning but on the other hand returns after settlement request. As a result, secondary treatments may be necessary to treat the disease.

Refractory follicular Cancer
Refractory is a term used to describe a disease that does not respond to the claim. In follicular cancer, this means that the abnormal cell increase does not improve sufficiently with the initial treatment for remission. As a result, secondary treatments may be necessary to treat the disease.

Factors for the decision to apply for a settlement
There are several factors that will influence claim decisions for a patient with relapsed or refractory follicular cancer. These include:

Previous treatment regimen
Remission period of the last claim
Sympt40mes of cancer
In most cases, the secondary claim should be different from the initial treatment method to increase the likelihood of successful remission.

Claims Options
There are several treatments that can be used in the relapsed or refractory follicular lymphoma claim, including chemotherapy, radiotherapy, monoclonal antibodies, and radioimmunotherapy.

High-dose chemotherapy, with autologous graft or stem cell allogeneic, can be effective in the relapsed follicular lymphoma claim to prolong the remission period.

Radiation therapy involves the use of lymphoma-oriented radiation waves to destroy cancer cells and induce remission.

Monoclonal antibodies such as rituximab (Rituxan), which are used alone or in combination with other claims methods, can also be effective.

Radioimmunotherapy (only or in combination with chemotherapy): Concerns radiation therapy and the immune system to destroy cancer cells, by attaching a radioactive compound to the monoclonal antibody drug, thus Providing radiation therapy directly to lymphoma cells. This occurs because the monoclonal antibody influenza to the CD20 antigen protein on the surface of lymphocyte cells.

Radioimmunotherapy medications are very effective in inducing remission that tips once used in an appropriate way. The drugs available in the radioimmunotherapy business include:

Tositumomab of Iodine 131 (Bexxar)

Y90 Ibritumomabtiuxetan (Zevalin)

Bendamustine (Treanda) can sometimes also be used in the relapsed or refractory lymphoma claim.

Transformed lymphoma

Approximately one-third of patients with follicular lymphoma will have histological transformation, also known as transformed lymphoma. This is usually more aggressive and requires more aggressive treatment approach. The claim may concern high-dose chemotherapy, in combination with a monoclonal antibody drug, such as rituximab. Alternative therapy options include radiotherapy and radioimmunotherapy.